Nour Abuhadra, MD

October 26, 2023

Dr. Noor Abuhadra and patient Shay Elkins discuss overcoming barriers to cancer treatment access and reimbursement. Shay shares her relatively smooth experience with insurance coverage, while Dr. Abuhadra emphasizes that healthcare teams will fight for patient coverage, especially when treatments are backed by research and FDA approval. Dr. Abuhadra also mentions having a financial clearance department to handle denials and secure approvals, as well as training staff to fill out prior authorization forms. Shay underlines the importance of self-advocacy and leveraging online communities for both emotional support and practical advice.

October 26, 2023

Dr. Noor Abuhadra discusses managing adverse events in patients receiving TRODELVY (sacituzumab govitecan), a later-line systemic therapy for metastatic triple-negative breast cancer. Shay Elkins, a patient, shares her experience with significant side effects including diarrhea, low white blood cell counts, and hair loss, while Dr. Abuhadra emphasizes the need for proactive management of these issues to maximize treatment time and maintain quality of life.

October 26, 2023

Shay Elkins, a patient with metastatic triple-negative breast cancer, discussed her experience with second-line treatment. Dr. Noor provided insights into the positive outcomes from the ASCENT study.

October 17, 2023

Shay Elkins, a patient with triple negative breast cancer, shares her experience of relapse six months post-treatment, eventually leading her to seek a second opinion for her recurring symptoms. Dr. Noor Abuhadra discusses second-line treatment options for metastatic triple negative breast cancer, emphasizing newer therapies like antibody drug conjugates and PARP inhibitors, and highlights the evolving landscape that offers hope for patients.